Viemed Healthcare, Inc. · NASDAQ:VMD
Viemed Healthcare — Q2 2026 Earnings Presentation
10 slides from Viemed Healthcare's earnings presentation, Aug 3, 2026
Slide 1: Financial Supplement Second Quarter 2026
1 Financial Supplement Second Quarter 2026 August 3, 2026 NASDAQ: VMD Viemed Healthcare, Inc.
Slide 2: Disclaimers: Forward Looking Statements
Disclaimers Forward Looking Statements Certain statements contained in this Financial Supplement may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian
Slide 3: Key Themes for Q2 2026
Key Themes for Q2 2026 3 Delivered record quarterly revenue of $78.1 million and the largest ventilator census in Company history, as accelerating ventilator growth, record PAP and sleep resupply patient volumes, and continued expansion of our women's health offerings drove first-half momentum that
Slide 4: Financial and Operational Highlights
Financial and Operational Highlights 4 (expressed in thousands of U.S. Dollars, except operational information). (1) Refer to “Adjusted EBITDA" in this presentation for the definition of Adjusted EBITDA and a reconciliation to its most comparable GAAP measure. (2) Vent Patients represents the number
Slide 5: Service, Payor and Revenue Mix
Medicare 40% Medicaid/ MCO 8% Medicare Advantage 22% Commercial 18% Other 12% Medicare 35% Medicaid/ MCO 10% Medicare Advantage 20% Commercial 24% Other 11% Ventilation 47% Oxygen 8% Sleep 22% Airway Clearance 7% Women’s Health 8% Staffing 7% Other 1% Q2 2026 Rental 68% Sales 32% Ventilation 54% Oxy
Slide 6: Revenue Highlights
Revenue Highlights 6 For the quarter ended 6/30/26 3/31/26 12/31/25 9/30/25 6/30/25 3/31/25 12/31/24 9/30/24 Rental Revenue (expressed in thousands of USD): Ventilators, non-invasive & invasive $36,411 $35,360 $35,888 $34,883 $33,819 $32,159 $33,173 $31,772 Other home medical equipment rentals $16,4
Slide 7: Liquidity Metrics
Liquidity Metrics 7 Positioned for growth • The Company maintains a healthy balance sheet with effectively no net debt as of June 30, 2026, providing significant financial flexibility. • As of June 30, 2026, the Company had $46 million in unfunded commitments available under its existing credit faci
Slide 8: Free Cash Flow TTM
Free Cash Flow 8 TTM For the quarter ended 6/30/26 6/30/26 3/31/26 12/31/25 9/30/25 Net cash provided by operating activities $ 60,781 $ 15,902 $ 8,071 $ 18,441 $ 18,367 Less: Purchase of property and equipment (31,545) (8,460) (6,712) (8,737) (7,636) Proceeds from sale of property and equipment 5,1
Slide 9: 2026 Annual Guidance – Commentary
2026 Annual Guidance – Commentary 9 Core Metrics • Net revenue of $314 million to $320 million, raised from $312 million to $320 million • Adjusted EBITDA of $64 million to $68 million, revised from $65 million to $69 million • Net capital expenditures of 8.5% to 10.0% of net revenue, lowered from 9
Slide 10: Adjusted EBITDA
Adjusted EBITDA 10 (a) Represents non-cash, equity-based compensation expense associated with option and RSU awards. (b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. (c) Represents impairments o